5-AZA
Showing 1 - 25 of >10,000
Tumors, Solid Tumors Trial run by the National Cancer Institute (NCI) (aza-TdC)
Recruiting
- Neoplasms
- Solid Tumors
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Recurrent Ependymoma Trial in Houston (5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group
Recruiting
- Recurrent Ependymoma
- 5-Azacytidine (5-AZA) group 1
- +2 more
-
Houston, TexasThe University of Texas Health Science Center at Houston
Aug 17, 2022
Prostatic Tumors, Prostate Tumors, Prostate Cancer Trial in New York (5-Azacitidine, all trans retinoic acid, Lupron)
Completed
- Prostatic Neoplasms
- +2 more
- 5-Azacitidine
- +2 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Aug 1, 2022
Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2023
Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)
Not yet recruiting
- Acute Myeloid Leukemia
- Azacitidine
- +2 more
-
Houston, TexasM.D. Anderson Cancer Center
Apr 17, 2023
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- STAT Inhibitor OPB-111077
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022
Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)
Recruiting
- Hodgkin's Lymphoma
-
Houston, TexasMD Anderson Cancer Center
Oct 5, 2022
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia
Recruiting
- Myelodysplastic Syndrome
- +2 more
- Navitoclax
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023
Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)
Terminated
- Leukemia
- Brentuximab Vedotin
- 5-Azacytidine
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 7, 2022
MDS, MDS/MPN Crossover Syndromes Trial in Cleveland (5-azacytidine, Decitabine)
Recruiting
- Myelodysplastic Syndromes
- MDS/MPN Crossover Syndromes
-
Cleveland, OhioCleveland Medical Center, University Hospitals Seidman Cancer Ce
Aug 10, 2022
Recurrent Leukemia, Refractory Leukemia Trial in Houston (Decitabine, Tegavivint)
Recruiting
- Recurrent Leukemia
- Refractory Leukemia
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Decitabine for Injection
- VENCLYXTO
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023
Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (Azacitidine, Pembrolizumab)
Active, not recruiting
- Melanoma and Other Malignant Neoplasms of Skin
- Metastatic Melanoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 31, 2022
Leukemia, Myeloid, Acute Trial in Guanzhou (Azacitidine, Chidamide)
Recruiting
- Leukemia, Myeloid, Acute
-
Guanzhou, Guandong, ChinaNanfang Hospital of Southern Medical University
Mar 6, 2022
MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)
Recruiting
- Myelodysplastic Syndromes
- Myeloproliferative Chronic Myelomonocytic Leukemia
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Leukemia, Myeloid, Acute Trial in Guanzhou (Azacitidine, Venetoclax)
Not yet recruiting
- Leukemia, Myeloid, Acute
-
Guanzhou, Guandong, ChinaNanfang Hospital of Southern Medical University
Jul 22, 2022
Acute Myelogenous Leukemia Trial in Rochester (Decitabine)
Completed
- Acute Myelogenous Leukemia
-
Rochester, New YorkUniversity of Rochester
Jul 1, 2022
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,
Recruiting
- Acute Myeloid Leukemia in Remission
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,
Completed
- Chronic Myelomonocytic Leukemia
- +3 more
- Azacitidine
- +2 more
-
Scottsdale, Arizona
- +3 more
Jan 12, 2023
Head and Neck Squamous Cell Carcinoma Trial in New Haven (5-Azacitadine)
Completed
- Head and Neck Squamous Cell Carcinoma
-
New Haven, ConnecticutSmilow Cancer Center at Yale New Haven Hospital
Feb 3, 2022
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,
Completed
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Lymphoma, T-Cell Trial in Charlottesville (Durvalumab, Pralatrexate, Romidepsin)
Recruiting
- Lymphoma, T-Cell
- Durvalumab
- +3 more
-
Charlottesville, VirginiaUniversity of Virginia
Mar 16, 2022
Acute Myeloid Leukemia (AML) Trial in Leipzig (VEN+AZA-5)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
-
Leipzig, GermanyUniversitätsklinikum Leipzig, Klinik und Poliklinik für Hämatolo
Apr 25, 2023
Acute Myeloid Leukemia Trial in Italy (Vidaza 100 milligram (mg) injection, Best Supportive Care)
Completed
- Acute Myeloid Leukemia
- Vidaza 100 milligram (mg) injection
- Best Supportive Care
-
Alessandria, AL, Italy
- +17 more
Jan 13, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,
Active, not recruiting
- Acute Myeloid Leukemia
- +5 more
- Decitabine
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023